1.
Bioorg Med Chem Lett
; 17(21): 6013-8, 2007 Nov 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-17827008
RESUMEN
Starting from adenosine triphosphate (ATP), the identification of a novel series of P2Y(12) receptor antagonists and exploitation of their SAR is described. Modifications of the acidic side chain and the purine core and investigation of hydrophobic substituents led to a series of neutral molecules. The leading compound, 17 (AZD6140), is currently in a large phase III clinical trial for the treatment of acute coronary syndromes and prevention of thromboembolic clinical sequelae.